We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Biosimilar Drugs Are Starting To Bring Competition to the Market, Study Finds

A line graph showing the number of trastuzumab claims in the US by month in 2019-2020.
Number of Medicare claims for trastuzumab originator (Herceptin) and 5 biosimilars, by month, 2019–20. Credit: Health Affairs.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

The U.S. biosimilar drug market emerged in 2015 to provide safe, effective, and more affordable alternatives to existing biologic drugs, but it has been slow to develop compared with Europe.

Now, eight years into the U.S. experience with biosimilars, researchers at the USC Schaeffer Center have studied the cancer drug trastuzumab (Herceptin) and its five biosimilar entrants as an example of biosimilars’ potential to reduce drug prices. Published today in Health Affairs, the study is one of the first to look at several biosimilar competitors in terms of U.S. market share, price, and physician prescribing.

“With multiple biosimilar competitors entering the U.S. market quickly, trastuzumab is the best example to date of biosimilars fulfilling their promise to reduce biologic drug prices,” said study co-author Alice Chen, associate professor and vice dean for research at the USC Sol Price School of Public Policy and senior fellow at the USC Schaeffer Center. “In just three years, the trastuzumab market displayed important hallmarks of competition: doctors could choose among six products; new entrants rapidly captured market share from the originator; and prices steadily declined on all six options. Prices of some versions declined by more than half, and the originator lost half of the market.”

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Researchers evaluated changes in average sales price, net price, and the extent to which the first biosimilar retained its advantage over later biosimilar entrants. Data show that the originator, Herceptin, began losing market share immediately after the first biosimilar, Kanjinti, entered the market. Herceptin continued to lose market share with subsequent entrants including Ogivri, Trazimera, Herzuma, and Ontruzant.

The data also show that while the existence of biosimilar options did not expand the total market for trastuzumab, multiple biosimilar products were viable and resulted in declining average sales price of all products.

“Our analysis applies to a physician-administered drug under Medicare Part B, and provides the best evidence so far that biosimilars can reduce originator drug prices quickly, in the same way that generics reduce prices of small-molecule drugs,” said co-author Karen Van Nuys, executive director of the Value of Life Sciences Innovation program and a senior fellow at the USC Schaeffer Center. “Our findings support the growing body of evidence that biosimilars do in fact reduce biologic drug prices in the physician-administered market. Whether they can do the same in the retail drug market remains to be seen, as the industry brings more of these products to the market.”

Reference: Chen AJ, Kaiser KM, Gascue L, Manetas MA, Van Nuys K. Cancer drug Trastuzumab and its biosimilars compete on price for market share: Study examines market share competition for cancer drug trastuzumab and its biosimilars. Health Affairs. 2023;42(6):779-784. doi: 10.1377/hlthaff.2022.01448

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.